James Mack, president and CEO since 1995 and chairman since 1999, has announced he will step down. The company will separate the positions of board chairman and CEO and John Miller, currently lead director, will assume the position of non-executive chairman of the board. Mr Mack will remain a board member and advisor until his retirement on June 30, 2008.
Mr Klosk, joined Cambrex in October 1992 as vice president-administration. He was appointed executive vice president, administration in October 1996, and was promoted to the position of executive vice president and COO for Cambrex Pharma and Biopharmaceutical Business Unit in October 2003. In January 2005 Mr Klosk assumed direct responsibility for the BioPharmaceutical Business Unit as COO. In January 2007 he was appointed executive vice president and COO for the company.
Mr Klosk said: “I am excited about the opportunity to lead the Cambrex team as we focus on our growth initiatives in proprietary products and polymeric drug delivery, highly potent compounds, controlled substances and our growing pipeline of new custom development products.”